Effects of Evolocumab combined with Atorvastatin calcium in treatment of patients with ultra-high-risk acute coronary syndrome after percutaneous coronary intervention
Objective:To observe effects of Evolocumab combined with Atorvastatin calcium in treatment of patients with ultra-high-risk acute coronary syndrome after percutaneous coronary intervention(PCI).Methods:A prospective study was conducted on 120 patients with ultra-high-risk acute coronary syndrome admitted to this hospital from June 2022 to June 2023.They were divided into control group and observation group according to the random number table method,60 cases in each group.Both groups were treated with dual antiplatelet drugs before and after PCI.On this basis,the control group was treated with Atorvastatin calcium,while the observation group was treated with Evolocumab on the basis of the control group.Both groups were treated continuously for 6 months.The clinical efficacy,the levels of blood lipid indexes[total cholesterol(TC),triacylglycerol(TG),low-density lipoprotein cholesterol(LDL-C),high-density lipoprotein cholesterol(HDL-C)],inflammatory factors[high mobility group protein B1(HMGB1),amyloid protein A1(SAA1),CC chemokine ligand 19(CCL19)]and vascular endothelial function indexes[nitric oxide(NO),endothelin-1(ET-1)]levels before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 96.67%(58/60),which was higher than 78.33%(47/60)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of LDL-C,TG and TC in the observation group were lower than those in the control group,the level of HDL-C was higher than that in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of SAA1,HMGB1 and CCL19 in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the level of NO in the observation group was higher than that in the control group,the level of ET-1 was lower than that in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Evolocumab combined with Atorvastatin calcium in the treatment of the patients with ultra-high-risk acute coronary syndrome after PCI can improve the total effective rate of treatment,improve the levels of blood lipid indexes and vascular endothelial function indexes,and reduce the levels of inflammatory factors.Moreover,it is superior to simple Atorvastatin calcium treatment.
Ultra-high-riskAcute coronary syndromePercutaneous coronary interventionEvolocumabAtorvastatin calciumBlood lipidVascular endothelial function
NETL
NSTL
万方数据
